The stock of Dynavax Technologies Corporation (NASDAQ:DVAX) is a huge mover today! About 302,665 shares traded hands. Dynavax Technologies Corporation (NASDAQ:DVAX) has declined 36.05% since March 11, 2016 and is downtrending. It has underperformed by 41.51% the S&P500.
The move comes after 9 months negative chart setup for the $407.16 million company. It was reported on Oct, 14 by Barchart.com. We have $9.27 PT which if reached, will make NASDAQ:DVAX worth $44.79M less.
Analysts await Dynavax Technologies Corporation (NASDAQ:DVAX) to report earnings on November, 3. They expect $-0.74 earnings per share, up 9.76% or $0.08 from last year’s $-0.82 per share. After $-0.75 actual earnings per share reported by Dynavax Technologies Corporation for the previous quarter, Wall Street now forecasts -1.33% EPS growth.
Dynavax Technologies Corporation (NASDAQ:DVAX) Ratings Coverage
Out of 2 analysts covering Dynavax Technologies (NASDAQ:DVAX), 0 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 0 are positive. Dynavax Technologies has been the topic of 4 analyst reports since August 12, 2015 according to StockzIntelligence Inc. The firm has “Outperform” rating given on Monday, November 30 by RBC Capital Markets. The rating was upgraded by Zacks on Wednesday, August 12 to “Hold”. The stock of Dynavax Technologies Corporation (NASDAQ:DVAX) has “Neutral” rating given on Wednesday, April 27 by JP Morgan. The firm has “Sector Perform” rating given on Thursday, April 28 by RBC Capital Markets.
According to Zacks Investment Research, “Dynavax Technologies discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Dynavax’s clinical development programs are based on immunostimulatory sequences which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation.”
Insitutional Activity: The institutional sentiment decreased to 1.02 in 2016 Q2. Its down 0.04, from 1.06 in 2016Q1. The ratio worsened, as 18 funds sold all Dynavax Technologies Corporation shares owned while 34 reduced positions. 10 funds bought stakes while 43 increased positions. They now own 31.67 million shares or 4.27% less from 33.08 million shares in 2016Q1.
California State Teachers Retirement Sys accumulated 81,505 shares or 0% of the stock. Nationwide Fund Advisors accumulated 0% or 24,881 shares. Manufacturers Life The holds 0% or 27,406 shares in its portfolio. Blackrock Advisors Ltd Liability Corp owns 18,981 shares or 0% of their US portfolio. Group Inc One Trading Lp accumulated 102,189 shares or 0.02% of the stock. Boston Partners, a Massachusetts-based fund reported 123,378 shares. Dsc Advsrs Limited Partnership holds 1.42% or 155,000 shares in its portfolio. Price T Rowe Associate Md last reported 0% of its portfolio in the stock. Legal & General Grp Incorporated Public Ltd Com accumulated 0% or 6,235 shares. Trexquant Inv Lp, a Connecticut-based fund reported 25,012 shares. Wells Fargo & Mn has 0% invested in the company for 13,870 shares. The North Carolina-based Hatteras Funds Limited Com has invested 0.86% in Dynavax Technologies Corporation (NASDAQ:DVAX). The New York-based Financial Bank Of New York Mellon Corp has invested 0% in Dynavax Technologies Corporation (NASDAQ:DVAX). Putnam Invs Limited Liability Company, a Massachusetts-based fund reported 175,729 shares. Credit Suisse Ag holds 0% of its portfolio in Dynavax Technologies Corporation (NASDAQ:DVAX) for 33,597 shares.
Insider Transactions: Since May 12, 2016, the stock had 2 insider buys, and 0 insider sales for $57,940 net activity. Gray Eddie also bought $42,820 worth of Dynavax Technologies Corporation (NASDAQ:DVAX) shares. $15,120 worth of shares were bought by Janssen Robert on Thursday, May 12.
More notable recent Dynavax Technologies Corporation (NASDAQ:DVAX) news were published by: Seekingalpha.com which released: “Will Dynavax’ Hepsilav-B Ever Get Approved?” on October 14, 2016, also Investorplace.com with their article: “Dynavax Technologies Corporation (DVAX) Steals Back Gains on Pending Heplisav …” published on October 03, 2016, Investorplace.com published: “Dynavax Technologies Corporation (DVAX) Injected With 20%-Plus Gains” on September 06, 2016. More interesting news about Dynavax Technologies Corporation (NASDAQ:DVAX) were released by: Fool.com and their article: “Here’s Why Dynavax Technologies Corporation’s Stock Gained 14.5% In March” published on April 09, 2016 as well as Prnewswire.com‘s news article titled: “Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation …” with publication date: September 06, 2016.
DVAX Company Profile
Dynavax Technologies Corporation (Dynavax), incorporated on November 6, 2000, is a clinical-stage biopharmaceutical company. The Firm uses toll-like receptor (TLR) biology to discover and develop vaccines and therapeutics. The Company’s development programs are focused on vaccines and cancer immunotherapy. The Company’s lead vaccine product candidate is HEPLISAV-B, an investigational adult hepatitis B vaccine, which combines its TLR9 agonist adjuvant and recombinant hepatitis B surface antigen (rHBsAg). The Company’s lead cancer immunotherapy candidate is SD-101, a C Class CpG TLR9 agonist is selected for characteristics optimal for treatment of cancer, including high interferon induction. The Company’s SD-101 clinical program is intended to assess the preliminary efficacy of SD-101 in a range of tumors and in combination with a range of treatments. The Company’s advanced inflammatory disease candidate is AZD1419. The Company’s pipeline of product candidates for cancer immunotherapy includes DV281 and CpG-Nanoparticles, which are in the preclinical stage.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.